NDA 021882 · Novartis
Exjade
Deferasirox · Oral · Iron Chelator
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 17, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Nov 2, 2005
Approved uses
7
Original approval plus efficacy supplements
Registered trials
97
15 Phase 3, 2 recruiting
FAERS reports
22,940
20,778 serious, 7,078 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RENAL FAILURE, HEPATIC FAILURE, and GASTROINTESTINAL HEMORRHAGE Renal Failure Exjade can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders. Evaluate baseline renal function prior to starting or increasing Exjade dosing in all patients. Exjade is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m 2 . Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of...
What it is approved for
From the label in effect Jan 28, 2026.
Exjade is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron Overload Due to Blood Transfusions (Transfusional Iron Overload) Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. 1.2 Treatment of Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia Syndromes Exjade is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. 1.3 Limitations of Use The safety and efficacy of Exjade when administered with other iron chelation therapy have not been established.
Mechanism: Exjade (deferasirox) is an orally active chelator that is selective for iron (as Fe 3+ ). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 23, 2020 Supplement 33 · Efficacy OrphanLetterLetterLabel
- Jul 24, 2019 Supplement 30 · Efficacy OrphanLetterLabel
- May 24, 2019 Supplement 31 · Efficacy · priority review LabelLetter
- Dec 12, 2018 Supplement 28 · Efficacy · priority review OrphanLabelLetter
- May 11, 2018 Supplement 25 · Efficacy OrphanLabelLetter
- Jan 23, 2013 Supplement 15 · Efficacy LabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Nov 2, 2005 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewLetter
3 products under this application
- EXJADE · DEFERASIROX 125MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
- EXJADE · DEFERASIROX 250MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
- EXJADE · DEFERASIROX 500MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Deferasirox" as an intervention, any sponsor and status, largest first.
- A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00171821 · 1,784 participants · Start Apr 2005 · Primary completion May 2009
Drug: Deferasirox · For: Transfusion-dependent Iron Overload
Sites: Adelaide, Australia; Camperdown, Australia; Clayton, Australia · 97 sites in all
- Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00235391 · 1,683 participants · Start Oct 2005 · Primary completion Oct 2008
Drug: Deferasirox · For: Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia and 1 more
Sites: Little Rock, Arkansas; Berkeley, California; Orange, California · 141 sites in all
- Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00061750 · 595 participants · Start May 2003 · Primary completion Nov 2004
Drug: ICL670; deferoxamine · For: Beta-Thalassemia
Sites: Los Angeles, California; Oakland, California; Stanford, California · 7 sites in all
- An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00171210 · 506 participants · Start Oct 2004 · Primary completion Apr 2008
Drug: Deferasirox · For: Transfusional Iron Overload in β-thalassemia
Sites: Los Angeles, California; Oakland, California; Stanford, California · 49 sites in all
- Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsPivotal-lookingCompleted
Consorzio per Valutazioni Biologiche e FarmacologicheAcademic, hospital or other
NCT01825512 · 435 participants · Start Mar 17, 2014 · Primary completion Sep 21, 2017
Drug: Deferiprone; Deferasirox · For: Chronic Iron Overload
Sites: Lushnje, Albania; Tirana, Albania; Nicosia, Cyprus · 22 sites in all
- Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major ThalassemiaPivotal-lookingCompleted
Beni-Suef UniversityAcademic, hospital or other
NCT04292314 · 350 participants · Start Nov 1, 2019 · Primary completion Dec 20, 2020
Drug: Omega 3; Nigella Sativa Oil and 3 more · For: Iron Overload; Oxidative Stress; Thalassemia Major
Sites: Banī Suwayf, Egypt; Mecca, Saudi Arabia · 4 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00564941 · 309 participants (planned) · Start Dec 2007 · Primary completion Jul 2011
Drug: deferasirox · For: Myelodysplastic Syndromes; Beta-Thalassemia
Sites: Budapest, Hungary; Debrecen, Hungary; Pécs, Hungary · 4 sites in all
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional HemosiderosisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171171 · 252 participants · Start May 2004 · Primary completion Nov 2006
Drug: deferasirox · For: Beta-Thalassemia; Hemosiderosis
Sites: Cairo, Egypt; Beirut, Lebanon; Muscat, Oman · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,237
- diarrhoea2,082
- sickle cell anaemia with crisis1,617
- pyrexia1,362
- nausea1,273
- haemoglobin decreased1,252
- pneumonia1,152
- serum ferritin increased1,072
- malaise1,020
- vomiting1,003
- fatigue980
- abdominal pain829
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 379 |
| 2007 | 336 |
| 2008 | 402 |
| 2009 | 2,043 |
| 2010 | 2,487 |
| 2011 | 3,027 |
| 2012 | 2,694 |
| 2013 | 831 |
| 2014 | 1,693 |
| 2015 | 2,168 |
| 2016 | 1,311 |
| 2017 | 941 |
| 2018 | 750 |
| 2019 | 559 |
| 2020 | 553 |
| 2021 | 552 |
| 2022 | 656 |
| 2023 | 458 |
| 2024 | 452 |
| 2025 | 373 |
| 2026 | 274 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Exjade (Deferasirox)
2024 spending
$3.2M
Beneficiaries
46
232 claims
Per beneficiary
$68,983
$159.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,718,471 |
| 2021 | $8,578,931 |
| 2022 | $4,221,647 |
| 2023 | $2,925,424 |
| 2024 | $3,173,237 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis.
Yampayon K, Anantachoti P, Chongmelaxme B, et al. · Front Pharmacol 2023 · Systematic Review
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study.
Sarocchi M, Li J, Li X, et al. · Br J Haematol 2024 · Randomized Controlled Trial, Multicenter Study
- Stroke With Transfusions Changing to Hydroxyurea (SWiTCH).
Ware RE, Helms RW · Blood 2012 · Clinical Trial, Phase III, Multicenter Study
- Deferasirox for managing iron overload in people with myelodysplastic syndrome.
Meerpohl JJ, Schell LK, Rücker G, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Safety profiles of iron chelators in young patients with haemoglobinopathies.
Botzenhardt S, Li N, Chan EW, et al. · Eur J Haematol 2017 · Meta-Analysis, Review
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.